



PIPER RUDNICK^{LLP}
1200 NINETEENTH STREET, NW
WASHINGTON, DC 20036-2412
TELEPHONE: 202-861-3900
FACSIMILE: 202-223-2085

DOCKET NO.: 9511-102-27 CONT

ASSISTANT COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Re: Serial No.: 10/628,433
Applicant(s): Glenn C. RICE, et al.
Filing Date: July 29, 2003
For: FIBROCYTE-BASED VACCINE FORMULATIONS
Group Art Unit: 1632

SIR:


Attached hereto for filing are the following papers:

Information Disclosure Statement
List of Related Cases
Form PT-1449
Cited Documents (5)

Our check in the amount of \$ 0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

PIPER RUDNICK LLP


Steven B. Kelber
Attorney of Record
Registration No.: 30,073

Patrick R. Delaney
Registration No.: 45,338

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION: Glenn C. RICE, et al.

GROUP ART UNIT: 1632

SERIAL NUMBER: 10/628,433

EXAMINER:

FILED: July 29, 2003

FOR: FIBROCYTE-BASED VACCINE FORMULATIONS



INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Assistant Commissioner for Patents
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Sir:

Applicant(s) wish(es) to disclose the following information.

REFERENCES

- ☐ Applicant(s) wish(es) to make of record the documents listed on the attached Form PTO-1449. References AP through BL are already of record in parent application U.S. Serial No. 08/828,415, now allowed. Copies of the listed documents are attached, where required, as are either statements of relevancy or any readily available full or partial English translations of any non-English-language documents.

RELATED CASES

- ☐ Attached is a list of Applicant's(s') pending applications and issued patents which may be related to the present application. Copies of the documents, where required, are attached along with Form PTO-1449.

CERTIFICATION

The undersigned certifies that

- ☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application for the first time (to the knowledge of the undersigned, having made reasonable inquiry) not more than three months prior to the filing of this statement.
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.

BASIS FOR CONSIDERATION

This Information Disclosure Statement is filed:

- ☐ without fee and within three months of the filing date of the application.
- ☐ without fee and within three months of the date of entry of the U.S. national stage.
- ☐ without fee and before the mailing date of a first Office Action on the merits (to the knowledge of the undersigned).
- ☐ without fee and with the appropriate certification above.
- ☐ without fee and with a new CPA application.
- ☐ without fee and with a Request for Continued Examination.
- ☐ with fee and before the mailing date of any of a Final Office Action, Notice of Allowance or an action that otherwise closes prosecution (to the knowledge of the undersigned).
- ☐ with fee, appropriate certification above, and before payment of the Issue Fee.

DEPOSIT ACCOUNT

- ☐ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 50-1442.


Respectfully submitted,

PIPER RUDNICK LLP

Steven B. Kelber
Attorney of Record
Registration No. 30,073
Patrick R. Delaney
Registration No. 45,338

1200 Nineteenth Street, N.W.
Washington, DC 20036-2412
Telephone No. (202) 861-3900
Facsimile No. (202) 223-2085

DOCKET NO.: 9511-102-27 CONT



LIST OF RELATED CASES

Docket Number	Serial or Patent Number	Filing or Issue Date	Status or Patentee
*9511-102-27 CONT	10/628,433	July 29, 2003	Pending
9511-090-27	10/160,048	June 4, 2002	Pending
9511-073-27	5,849,307	December 15, 1998	Patented

The cases listed on this Notice of Related Cases include cases which may contain information that is material to patentability. The listing of a case on this Notice should not be taken as an indication or admission that any information contained therein is material. Prior art for each case listed on this Notice may have been cited. **The files corresponding to the listed cases, which are available to the Examiner, may not have not been examined to ascertain the materiality of any prior art therein.** Accordingly, the Examiner is requested to review the file for each case listed on this Notice in order to assess the materiality of such prior art.

*Present application; listed for information.

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE				DOCKET NO. 9511-102-27 CONT		SERIAL NO. 10/628,433	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)				APPLICANT Glenn C. RICE, et al.			
				FILING DATE July 29, 2003		GROUP ART UNIT 1632	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5,654,186	8/5/1997	CERAMI et al.		
	AB	5,849,307	12/15/98	METZ et al.		
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO	
AK	WO 02/098278 A2	12/12/02	WIPO (Equivalent to U.S. 10/160,048, filed June 4, 2002)	
	AL			
	AM			
	AN			
	AO			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	Taber's Cyclopedic Medical Dictionary (C.L. Thomas Ed., 16 th Ed., F.A. Davis Co., Philadelphia, p. 669, 1989)
AQ	Guo et al. (Science, 263:518-520, 1994)
AR	Koby (Immunology, W.H. Freeman & Co., NY, p. 242, 1994)
AS	Dictionary of Immunology, Herbert et al., Eds, 4 th Ed., Academic Press, London, pp. 42-43, 1995

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


Form PTO 1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

DOCKET NO.

9511-102-27

SERIAL NO.

10/628,433



LIST OF REFERENCES CITED BY APPLICANT
(Use Several Sheets if Necessary)

APPLICANT

Glenn C. RICE, et al.

FILING DATE

July 29, 2003

GROUP ART UNIT

1632

U.S. PATENT DOCUMENTS

EXAMINE R INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
	AC				
	AD				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AT	Bucala, R., et al., "Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair", Molecular Medicine, Volume 1, pp. 71-81 (1994).
	AU	Freudenthal, P.S., et al., "The Distinct Surface of Human Blood Dendritic Cells, As Observed After An Improved Isolation Method", Proc. Natl. Acad. Sci. USA, Volume 87, pp. 7698-7702 (1990).
	AV	Chu, T., et al., "The Normal Langerhans Cell and the LCH Cell", Br. J. Cancer, Volume 70, Suppl. XXIII, S4-S10 (1994).
	AW	Schall, T.J., et al., "Human Macrophage Inflammatory Protein α (MIP-1 α) and MIP-1 β Chemokines Attract Distinct Populations of Lymphocytes", J. Exp. Med., Volume 177, pp. 1821-1825 (1993).
	AX	Wahl, L.M., et al., "Inflammation", Wound Healing: Biochemical and Clinical Aspects, Cohen, et al. (eds.), Saunders Company, Philadelphia, pp. 40-62 (1992).
	AY	Geppert, T.D., et al., "Antigen Presentation by Interferon- γ -Treated Endothelial Cells and Fibroblasts: Differential Ability to Function as Antigen-Presenting Cells Despite Comparable Ia Expression", The Journal of Immunology, Volume 135, No. 6, pp. 3750-3762 (1985).
	AZ	Pober, J.S., et al., "Ia Expression by Vascular Endothelium is Inducible by Activated T Cells and by Human γ Interferon", J. Exp. Med., Volume 157, pp. 1339-1353 (1983).
	BA	Le Poole, I.C., et al., "A Novel, Antigen-Presenting Function of Melanocytes and Its Possible Relationship to Hypopigmentary Disorders", The Journal of Immunology, Volume 151, No. 12, pp. 7284-7292 (1993). (erroneously cited as "Poole, Volume 12" in specification)
	BB	Inaba, K., et al., "Dendritic Cells Pulsed with Protein Antigens In Vitro Can Prime Antigen-Specific, MHC-Restricted T Cells In Situ", J. Exp. Med., Volume 172, pp. 631-640 (1990).
	BC	Levin, D., et al., "Role of Dendritic Cells in the Priming of CD4 ⁺ T Lymphocytes to Peptide Antigen In Vivo", The Journal of Immunology, Volume 151, No. 12, pp. 6742-6750 (1993). (erroneously cited as "Volume 12")
	BD	Wang, R., et al., "Human Tumor Antigens Recognized by T Lymphocytes: Implications for Cancer Therapy", Journal of Leukocyte Biology, Volume 60, pp. 296-309 (1996).

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 9511-102-27	SERIAL NO. 10/628,433
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)				APPLICANT Glenn C. RICE, et al.	
				FILING DATE July 29, 2003	
				GROUP ART UNIT 1632	
	BE	Bhardwaj, N., et al., "Influenza Virus-Infected Dendritic Cells Stimulate Strong Proliferative and Cytolytic Responses from Human CD8+ T Cells", J. Clin. Invest., Volume 94, pp. 797-807 (1994).			
	BF	Bender, A., et al., "Inactivated Influenza Virus, when Presented on Dendritic Cells, Elicits Human CD8+ Cytolytic T Cell Responses", J. Exp. Med., Volume 182, pp. 1663-1671 (1995).			
	BG	Loken, M. R., et al., "Immunofluorescence of Surface Markers", Chapter 5, Flow Cytometry, Ormeron (ed.), Oxford University Press, Oxford, pp. 67-92 (1994).			
	BH	Clark, E.A., et al., "How B and T Cells Talk to Each Other", Nature, Volume 367, pp. 425-429 (1994).			
	BI	James, S. P., "Measurement of Basic Immunologic Characteristics of Human Mononuclear Cells", Current Protocols in Immunology, Coligan, et al. (eds.), John Wiley and Sons, Inc., New York, pp. 7.10.1-7.11.4 (1994). (cited as "Jasmes" in specification).			
	BJ	Zar, J.H., "Nonparametric Analysis of Variance", Section 11.4, Biostatistical Analysis, Prentice Hall, Englewood Cliffs, New Jersey, pp. 176-179 (1984). (cited as "p. 718" in specification).			
	BK	Young, J.W., et al., "Accessory Cell Requirements for the Mixed-Leukocyte Reaction and Polyclonal Mitogens, as Studied with a New Technique for Enriching Blood Dendritic Cells", Cellular Immunology, Volume 111, pp. 167-182 (1988).			
	BL	Sprent, J., "Restricted Helper Function of F ₁ Hybrid T Cells Positively Selected to Heterologous Erythrocytes in Irradiated Parental Strain Mice", J. Exp. Med., Volume 147, pp. 1142-1158 (1978). (cited as pp. "1159" in specification)			

